What Iter Investments does

Iter Investments is a Fort Lauderdale-based venture capital firm founded in 2021 that invests exclusively in early-stage companies developing alternative therapeutics for mental and behavioral health conditions, with a thematic concentration in psychedelic-based treatments and adjacent technologies. The firm operates a single flagship fund that closed at $20 million in July 2022 and has deployed capital across at least 20 portfolio companies spanning the full alternative therapeutics value chain, including pharmaceutical API manufacturers (Psygen), drug developers targeting addiction, depression, PTSD, and traumatic brain injury (Beckley Psytech, Awakn Life Sciences, Apex Labs, Sensorium Therapeutics, Psilera, Reset Pharma, Clairvoyant, Freedom Bio), digital therapeutics and VR (TRIPP, PsyTech, Muse), clinical training platforms (Fluence), research infrastructure (Quantified Citizen), retreat experiences (Beckley Retreats), and a MAPS-linked revenue-share vehicle for MDMA-assisted therapy.

The firm generates revenue through conventional venture fund economics, primarily management fees on its $20M AUM with potential carried interest on exits; LP identities are not publicly disclosed and investment access is restricted to qualified investors. Its competitive positioning rests on a multidisciplinary team that pairs an FDA regulatory attorney, board-certified physicians including a lead facilitator in an FDA Phase 2 psilocybin trial, a PhD researcher at Imperial College's Centre for Psychedelic Research, IP specialists, and operators with prior exits at Headspace, Talkspace, and Stryker. Beyond the fund itself, Iter controls Nucleus Holdings, a wholly-owned subsidiary consolidating data and media assets across the psychedelic industry, and the firm's leadership has founded or represents advocacy organizations (Mr. Psychedelic Law, MindArmy, TheraPsil, and the Psychedelic Pharmacists Association) that shape the regulatory environment in which the portfolio operates.

Name

Iter Investments

Legal name

Iter Investments

Website

https://iterinvestments.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Iter Investments is a Fort Lauderdale-based venture capital firm that deploys early-stage capital into psychedelic and alternative therapeutics companies developing treatments for mental and behavioral health conditions via a $20 million fund and active regulatory advocacy.

Ownership category

akta.pro rank

Product category

Venture Capital / Mental Health Investment

NAICS

Other Investment Pools and Funds (5259), Other Financial Investment Activities (5239), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Debt Providers (FSANAAAL)

akta.pro secondary industry

Institutional Capital Introduction (LP/Family Office/Endowment Matching) (FSAEALAI)

Keywords

• Venture capital investing
• Alternative therapeutics funding
• Psychedelic medicine investment
• Mental health startups
• Early-stage equity funding

Headquarters

HQ city

Fort Lauderdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Venture Capital Fund Management: Iter Investments generates returns by investing in early-stage companies developing alternative therapeutics for mental and behavioral health. The firm closed its first fund at $20 million and deploys capital into portfolio companies across the psychedelic industry value chain.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Iter Investments is a venture capital firm that raises capital from limited partners and deploys it as early-stage equity into companies developing alternative therapeutics — including psychedelic-based therapies, biotech, digital health platforms, and clinical services — for mental and behavioral health conditions. The firm's $20 million debut fund backs founders across the psychedelic and alternative therapeutics value chain, supplemented by portfolio management, due diligence, and ecosystem access via its wholly-owned Nucleus Holdings platform.

Product overview

Iter Investments is a venture capital firm operating as a single unified investment fund focused on the alternative therapeutics space for mental and behavioral health. The firm deploys capital into early-stage companies across the psychedelic and alternative therapeutics ecosystem, supported by a team of experienced investors, legal experts, scientists, and clinicians. Iter Investments Fund represents the core investment vehicle, while the firm provides venture capital investment services including opportunity sourcing, due diligence, and portfolio management to support companies developing innovative mental health treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Iter Investments Fund Flagship closed-end venture capital fund that deploys equity capital into early-stage companies developing alternative therapeutics for mental and behavioral health conditions. Targeted at qualified investors (limited partners). Fund closed at $20 million in July 2022.
• Venture Capital Investment Services

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• Mr. Psychedelic LawcoreOthersFounded by Managing Partner Dustin Robinson and Clinical Lead Michelle Weiner, Mr. Psychedelic Law is a 501(c)(4) organization dedicated to driving responsible legal reform of psilocybin mushrooms to improve mental health outcomes. It has a Medical and Legal Advisory Board with top medical and legal minds in the psychedelic industry.
• MindArmycoreOthersCo-founded by Managing Partner Dustin Robinson, MindArmy is a 501(c)(3) organization demanding that the federal government de-schedule psychedelics so humans can access psychedelic-assisted therapy for mental health treatment.
• TheraPsilminorOthersIntellectual Property Lead David Wood represents TheraPsil, a non-profit coalition dedicated to obtaining legal access to psilocybin-assisted psychotherapy for terminally ill Canadians. Mission includes facilitating compassionate access to psilocybin for therapeutic use, public education, professional training, and research.
• Psychedelic Pharmacists AssociationminorOthersManaging Partner Dustin Robinson's law firm represents the Psychedelic Pharmacists Association, a non-profit devoted to pharmacists advancing psychedelics as medicines. Vision is to serve as the premier resource for pharmacists advancing psychedelic therapies.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Noetic Fund: An early-stage venture capital fund that invests in psychedelic medicine and mental health therapeutics. Direct comparable to Iter as a thematic specialist VC firm deploying institutional and family-office capital into psychedelic drug developers and adjacencies.

Broad incumbents

• ATAI Life Sciences: Public (NASDAQ: ATAI) clinical-stage biopharmaceutical company and psychedelic investment holding vehicle developing mental health treatments. Operates in the same psychedelic ecosystem as Iter's portfolio companies and is a logical strategic acquirer or co-investor for Iter's positions.
• Compass Pathways: Public (NASDAQ: CMPS) mental health company developing COMP360 psilocybin therapy for treatment-resistant depression. Competes with Iter portfolio companies (Beckley Psytech, Wesana) for clinical trial readouts and capital in psychedelic depression treatment.
• MindMed: Public (NASDAQ: MNMD) psychedelic medicine company developing LSD and MDMA-inspired programs for anxiety and other indications. A prominent public-market participant whose valuation dynamics affect LP appetite for psychedelic-focused funds like Iter.
• Cybin Inc. Public (NYSE American: CYBN) clinical-stage psychedelics company developing psilocybin-based therapeutics for depression and addiction. Competes with multiple Iter portfolio companies (Awakn, Clairvoyant) for capital and clinical milestones in psychedelic mental health.
• RA Capital Management: Healthcare-focused crossover and venture capital firm with active investment activity in the psychedelic therapeutics space (e.g., Compass, MindMed). A larger, more diversified biotech VC that competes with Iter for primary allocations in psychedelic Series A and B rounds.
• ARCH Venture Partners: Large early-stage biotech venture firm that has historically led multi-hundred-million dollar rounds in psychedelic developers. A scale competitor for Iter in late-seed and Series A psychedelic financings.
• Bessemer Venture Partners: Large multi-stage venture firm with a deep healthcare practice that invests across biotech and digital health. A generalist incumbent whose participation in psychedelic rounds (Beckley, TRIPP-adjacent) creates competitive overlap with Iter's portfolio companies.
• Khosla Ventures: Large generalist venture firm with a health and bio practice that has backed psychedelic and mental-health-adjacent companies. Comparable to Iter as a high-conviction thematic investor in early-stage therapeutics but with vastly larger AUM.
• GH Research: Public (NASDAQ: GHRS) clinical-stage psychedelics company developing mebufotenin (5-MeO-DMT) for treatment-resistant depression. Another public biotech operator in the same psychedelic-mental-health category whose market dynamics influence LP appetite for funds like Iter.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/iter-investments

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iter Investments